Find in Library
Search millions of books, articles, and more
Indexed Open Access Databases
Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia
oleh: Klaus Geissler, Eva Jäger, Agnes Barna, Michael Gurbisz, Temeida Graf, Elmir Graf, Thomas Nösslinger, Michael Pfeilstöcker, Sigrid Machherndl-Spandl, Reinhard Stauder, Armin Zebisch, Heinz Sill, Leopold Öhler, Rajko Kusec, Gregor Hörmann, Peter Valent
Format: | Article |
---|---|
Diterbitkan: | MDPI AG 2020-08-01 |
Deskripsi
We have originally reported that colony-forming units granulocyte/macrophage (CFU-GM) formation is an in vitro feature of chronic myelomonocytic leukemia (CMML) and a strong predictor for short survival. Elucidation of the molecular basis underlying this in vitro phenomenon could be helpful to define molecular features that predict inferior outcome in patients. We studied the correlation between the mutational landscape and spontaneous colony formation in 164 samples from 125 CMML patients. As compared to wildtype samples, spontaneous in vitro CFU-GM formation was significantly increased in samples containing mutations in <i>NRAS</i>, <i>CBL</i> and <i>EZH2</i> that were confirmed as independent stimulatory factors by multiple regression analysis. Inducible expression of mutated <i>RAS</i> but not <i>JAK2</i> was able to induce growth factor independence of Ba/F3 cells. Whereas high colony CFU-GM growth was a strong unfavorable parameter for survival (<i>p</i> < 0.00001) and time to transformation (<i>p</i> = 0.01390), no single mutated gene had the power to significantly predict for both outcome parameters. A composite molecular parameter including <i>NRAS/CBL/EZH2</i>, however, was predictive for inferior survival (<i>p</i> = 0.00059) as well as for increased risk of transformation (<i>p</i> = 0.01429). In conclusion, we show that the composite molecular profile <i>NRAS/CBL/EZH2</i> derived from its impact on spontaneous in vitro myeloid colony formation improves the predictive power over single molecular parameters in patients with CMML.